TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04599868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h\& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h\& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed.
Study: NCT01173029

Intervention type: DRUG
Intervention: Anti-hypertensive drug treatment
Description: Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.

Intervention type: DRUG
Intervention: Anti-hypertensive drug treatment
Description: Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
Study: NCT02775110

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natalizumab discontinuation
Description: Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natalizumab discontinuation
Description: Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
Study: NCT00826358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: Once, please see Arm Description for more details.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: Once, see Arm Description for more detail

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: once, see Arm Description for more detail
Study: NCT00276094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg
Description: 1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Description: 1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonhormonal vaginal lubricant
Description: Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonhormonal vaginal lubricant
Description: Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nonhormonal vaginal lubricant
Description: Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
Study: NCT04373499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Teach to Goal
Description: Virtual Teach-to-Goal is an educational module that teaches children how to use their inhaler properly; this is done with an IPAD. In the module, the child will complete a series of questions as a pre-assessment, watch a video about how to use the inhaler properly, and then answer a series of questions as a post-assessment. If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention
Description: There is a handout that describes proper inhaler technique. The RA reads the handout to the child.
Study: NCT01869361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control drug
Study: NCT01480609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retigabine / Ezogabine
Description: Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retigabine / Ezogabine
Description: Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
Study: NCT03617575

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: apo-Lactoferrin
Description: 1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf \[total of 1.5 mg iron\]) in a maize porridge (extrinsically labeled)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: holo-Lactoferrin
Description: 1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FeSO4
Description: 1.5 mg FeSO4 as 54Fe in a maize porridge

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1. FeSO4
Description: 10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FeSO4 after 1 day break
Description: 10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FeSO4 after 2 day break
Description: 10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period
Study: NCT04520256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Platform for Social Support & Friendly Competition
Description: An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
Study: NCT02531633

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match prednisone
Description: Placebo to match prednisone will be provided as tablets.
Study: NCT02533037

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Instability Tools
Description: Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle Destabilization Shoes
Description: Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
Study: NCT00999583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOETINE ALPHA
Description: 5 injections of 40000 UI of EPO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Usual take care of cardiac arrest
Study: NCT01938378

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Octaplas™
Description: octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
Study: NCT04684498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir phosphate capsules
Description: Treatment group vs. Control group
Study: NCT02531633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match prednisone
Description: Placebo to match prednisone will be provided as tablets.
Study: NCT00777400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: 1 mg/kg of efalizumab administered sub q once weekly
Study: NCT03177447

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ENABLE CHF-PC
Description: An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
Study: NCT01898949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Exposure
Description: Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
Study: NCT00902421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Description: escitalopram 10mg once daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimuscarinics
Description: Antimuscarinics for 3 months
Study: NCT01386541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BYK324677
Description: capsules, administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BYK324677
Description: capsules, administered orally
Study: NCT04289077

Intervention type: OTHER
Intervention: Questionnaires
Description: - Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
Study: NCT00531297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic posterior mesorectal resection
Description: 6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
Study: NCT02046850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
Study: NCT02531633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match prednisone
Description: Placebo to match prednisone will be provided as tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match prednisone
Description: Placebo to match prednisone will be provided as tablets.
Study: NCT02046850

Intervention type: DRUG
Group type: OTHER
Intervention: rifampicin
Description: Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
Study: NCT00701636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
Study: NCT00928278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Inhaled, 300/150, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: Inhaled, 300/150, single dose
Study: NCT04684498

Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir phosphate capsules
Description: Treatment group vs. Control group
Study: NCT01451359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBronchial Valve
Description: The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
Study: NCT01726998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait therapy
Description: Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional gait training
Description: Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
Study: NCT02531633

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match prednisone
Description: Placebo to match prednisone will be provided as tablets.
Study: NCT03083678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
Study: NCT01051947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: 10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: dosage prescribed prior to starting on study
Study: NCT04215276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Valsalva maneuver
Description: pressure during Valsalva maneuver was measure using sphygmomanometer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: patient was not given any intervention
Study: NCT05885620

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drinking reminder and cognitive task (smartwatch-based application)
Description: task A: prompt to drink some water task B: prompt to circle bells on a sheet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drinking reminder and cognitive task (smartwatch-based application)
Description: task A: prompt to drink some water task B: prompt to circle bells on a sheet
Study: NCT03849937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Changing Talk Online (CHATO)
Description: Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changing Talk Online (CHATO)
Description: Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
Study: NCT03488459

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine preoperative information from a nurse
Description: Routine preoperative information from a nurse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional information support from a psychologist
Description: Routine preoperative information from a nurse + additional information support from a psychologist.
Study: NCT00928278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Inhaled, 300/150, single dose + oral activated charcoal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment D
Description: Inhaled, 300/150, single dose + oral activated charcoal block
Study: NCT00220805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
Description: The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin (Human) 25%, United States Pharmacopeia (USP)
Description: Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
Study: NCT02045225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction of social anxiety & substance use in gay/bi men
Description: The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
Study: NCT04255316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified method of eversion carotid endarterectomy
Description: Mini approach for CCA bifurcation - Clamping ICA, ECA and CCA - ICA is cut off with a scalpel at the mouth itself - Dissection of the ICA and ECA in the distal direction to the distal border of the atherosclerotic plaque - Endarterectomy - Performing of a new bifurcation of the CCA with prolene 7/0
Study: NCT05122923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serious Game S'TIM
Description: Video Game S'tim : the patient is inside a bedroom and he has to find a friend outside. this game will study the orientation, the memory of the patient
Study: NCT01587638

Intervention type: DRUG
Intervention: carvedilol
Description: carvedilol immediate-release (IR) and carvedilol controlled-release (CR)

Intervention type: DRUG
Intervention: cardio selective betablocker
Description: atenolol, metoprolol succinate, and metoprolol tartrate
Study: NCT03998748

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Genetic Feedback
Description: Participants will be told either that they have or do not have a genetic predisposition to developing depression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Genetic Feedback
Description: Participants will be told either that they have or do not have a genetic predisposition to developing depression.
Study: NCT04255316

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard method of eversion carotid endarterectomy
Description: standard eversion technic
Study: NCT01084525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104 (steroid) 3 mg
Description: OTO-104 3 mg dose cohort, single intratympanic injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
Study: NCT04573426

Intervention type: DRUG
Intervention: Acetaminophen
Description: 1,000mg liquid acetaminophen

Intervention type: DRUG
Intervention: Acetaminophen
Description: 1,000mg liquid acetaminophen

Intervention type: DRUG
Intervention: Placebo
Description: Liquid placebo solution

Intervention type: DRUG
Intervention: Placebo
Description: Liquid placebo solution

Intervention type: DRUG
Intervention: Placebo
Description: Liquid placebo solution

Intervention type: BEHAVIORAL
Intervention: Weight stigma vignette
Description: Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight

Intervention type: BEHAVIORAL
Intervention: Weight stigma vignette
Description: Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight

Intervention type: BEHAVIORAL
Intervention: Weight stigma vignette
Description: Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight

Intervention type: BEHAVIORAL
Intervention: Control vignette
Description: Short vignette meant to have no effect on emotion describing a generic promotion process